151 related articles for article (PubMed ID: 17182827)
1. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RB; Peehl DM; Feldman D
J Nutr; 2007 Jan; 137(1 Suppl):205S-210S. PubMed ID: 17182827
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway.
Moreno J; Krishnan AV; Peehl DM; Feldman D
Anticancer Res; 2006; 26(4A):2525-30. PubMed ID: 16886660
[TBL] [Abstract][Full Text] [Related]
3. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer.
Krishnan AV; Moreno J; Nonn L; Malloy P; Swami S; Peng L; Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):694-702. PubMed ID: 17229571
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RS; Gardner C; Brooks JD; Peehl DM; Feldman D
Int J Cancer; 2009 May; 124(9):2050-9. PubMed ID: 19127598
[TBL] [Abstract][Full Text] [Related]
5. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.
Moreno J; Krishnan AV; Swami S; Nonn L; Peehl DM; Feldman D
Cancer Res; 2005 Sep; 65(17):7917-25. PubMed ID: 16140963
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment.
Krishnan AV; Feldman D
Endocr Relat Cancer; 2010 Mar; 17(1):R19-38. PubMed ID: 19926709
[TBL] [Abstract][Full Text] [Related]
7. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer.
Wang JY; Swami S; Krishnan AV; Feldman D
Prostate; 2012 Nov; 72(15):1628-37. PubMed ID: 22457201
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer.
Moreno J; Krishnan AV; Feldman D
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):31-6. PubMed ID: 16024246
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.
Krishnan AV; Srinivas S; Feldman D
Dermatoendocrinol; 2009 Jan; 1(1):7-11. PubMed ID: 20046582
[TBL] [Abstract][Full Text] [Related]
10. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity.
Krishnan AV; Moreno J; Nonn L; Swami S; Peehl DM; Feldman D
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V74-80. PubMed ID: 18290727
[TBL] [Abstract][Full Text] [Related]
11. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells.
Rao A; Coan A; Welsh JE; Barclay WW; Koumenis C; Cramer SD
Cancer Res; 2004 Mar; 64(6):2143-7. PubMed ID: 15026355
[TBL] [Abstract][Full Text] [Related]
13. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window.
Nayak NR; Sengupta J; Ghosh D
Contraception; 1998 Aug; 58(2):111-7. PubMed ID: 9773266
[TBL] [Abstract][Full Text] [Related]
14. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway.
Zhang L; Li L; Jiao M; Wu D; Wu K; Li X; Zhu G; Yang L; Wang X; Hsieh JT; He D
Cancer Lett; 2012 Oct; 323(1):48-57. PubMed ID: 22484470
[TBL] [Abstract][Full Text] [Related]
15. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
16. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.
Agarwal R
Biochem Pharmacol; 2000 Oct; 60(8):1051-9. PubMed ID: 11007941
[TBL] [Abstract][Full Text] [Related]
17. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
Hughes D; Otani T; Yang P; Newman RA; Yantiss RK; Altorki NK; Port JL; Yan M; Markowitz SD; Mazumdar M; Tai HH; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2008 Sep; 1(4):241-9. PubMed ID: 19138967
[TBL] [Abstract][Full Text] [Related]
18. Dietary genistein inhibits metastasis of human prostate cancer in mice.
Lakshman M; Xu L; Ananthanarayanan V; Cooper J; Takimoto CH; Helenowski I; Pelling JC; Bergan RC
Cancer Res; 2008 Mar; 68(6):2024-32. PubMed ID: 18339885
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Thill M; Terjung A; Friedrich M
Eur J Gynaecol Oncol; 2014; 35(4):341-58. PubMed ID: 25118473
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin biosynthesis, transport, and signaling in corpus luteum: a basis for autoregulation of luteal function.
Arosh JA; Banu SK; Chapdelaine P; Madore E; Sirois J; Fortier MA
Endocrinology; 2004 May; 145(5):2551-60. PubMed ID: 14736737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
